Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

Leukemia Research

Volumn 38, Issue 5, 2014, Pages 557-563

  Delforge, Michel ^a   Selleslag, Dominik ^b   Beguin, Yves ^c   Triffet, Agnès ^d   Mineur, Philippe ^e   Theunissen, Koen ^f   Graux, Carlos ^g   Trullemans, Fabienne ^h   Boulet, Dominique ⁱ   Van Eygen, Koen ^j   Noens, Lucien ^k   Van Steenweghen, Steven ^l   Lemmens, Jan ^m   Pierre, Pascal ⁿ   D'hondt, Randal ^o   Ferrant, Augustin ^p   Deeren, Dries ^q   Van De Velde, Ann ^r   Wynendaele, Wim ^s   André, Marc ^g   De Bock, Robrecht ^t   Efira, André ^u   Breems, Dimitri ^v   Deweweire, Anne ^w   Geldhof, Kurt ^x   Pluymers, Wim ^y   Harrington, Amanda ^z,aa   MacDonald, Karen ^z   Abraham, Ivo ^z,aa   Ravoet, Christophe ^ab,ac   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b General Hospital St Jan   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Centre Hospitalier Universitaire de Charleroi   (Belgium)

^e Grand Hospital de Charleroi   (Belgium)

^f Jessa Ziekenhuis   (Belgium)

^g UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ Clinique Saint Joseph   (Belgium)

^j Groeninge Ziekenhuis   (Belgium)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

^l Centre Hospitalier Regional de La Citadelle   (Belgium)

^m Algemeen Ziekenhuis St Augustinus   (Belgium)

ⁿ Cliniques du Sud Luxembourg   (Belgium)

^o Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^p CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^q Heilig Hart Ziekenhuis   (Belgium)

^r ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^s Algemeen Ziekenhuis Imelda   (Belgium)

^t MIDDELHEIM HOSPITAL   (Belgium)

^u BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^v ZiekenhuisNetwerk Antwerpen   (Belgium)

^w Réseau Hospitalier de Médecine Sociale Baudour ^*  (Belgium)

^x Jan Yperman Ziekenhuis   (Belgium)

^y Novartis Pharma   (Belgium)

^z Matrix45   (United States)

^aa UNIVERSITY OF ARIZONA   (United States)

^ab Centre Hospitalier Jolimont Lobbes   (Belgium)

^ac JULES BORDET INSTITUTE   (Belgium)

more..

Author keywords

Cardiac death; Chelation therapy; Iron overload; Myelodysplastic syndromes; Transfusion; Transfusion dependency

Indexed keywords

CARDIAC DEATH; CHELATION THERAPY; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; TRANSFUSION; TRANSFUSION DEPENDENCY;

AGED; BLOOD TRANSFUSION; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 84899082162     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.02.003     Document Type: Article

References (31)

1. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007, 31:S2-S6.
2. Sekeres M.A. The myelodysplastic syndromes. Exp Opin Biol Ther 2007, 7(March (3)):369-377.
3. Jabbour E., Kantarjian H.M., Koller C., Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008, 112(5):1089-1095.
4. Tefferi A. Myelodysplastic syndromes-many new drugs, little therapeutic progress. Mayo Clin Proc 2010, 85:1042-1045.
5. List A.F. Identifying best practices in the monitoring and treatment of iron overload in myelodysplastic syndrome. Hematol Oncol Clin North Am 2006, 20(Supplement 1):8-14.
6. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
7. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(11):858-861.
8. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
9. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87:1286-1306.
10. Greenberg P.L. The myelodysplastic syndromes. Hematology: basic principles and practice 2000, 1106-1129. Churchill Livingstone, New York, NY. 3rd ed. R. Hoffman, E. Benz, S. Shattil, H. Cohen (Eds.).
11. Kasner M.T., Luger S.M. Update on the therapy for myelodysplastic syndrome. Am J Hematol 2009, 84:177-186.
12. Cazzola M., Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005, 352:536-538.
13. Brittenham G.M. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
14. Porter J.B. Practical management of iron overload. Br J Haematol 2001, 115:239-252.
15. Hoffbrand A.V., Taher A., Cappellini M.D. How I treat transfusional iron overload. Blood 2012, 120:3657-3659.
16. Gattermann N., Finelli C., Porta M.D., Fenaux P., Ganser A., Guerci-Bresler A., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34:1143-1150.
17. Gattermann N., Jarisch A., Schlag R., Blumenstengel K., Goebeler M., Groschek M., et al. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur J Haematol 2012, 88:260-268.
18. Greenberg P.L., Koller C.A., Cabantchik Z.I., Warsi G., Glynos T., Paley C., et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010, 34:1560-1565.
19. Porter J., Galanello R., Saglio G., Neufeld E.J., Vichinsky E., Cappellini M.D., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008, 80:168-176.
20. Cappellini M.D., Porter J., El-Beshlawy A., Li C.K., Seymour J.F., Elalfy M., et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010, 95:557-566.
21. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010, 34:864-870.
22. Neukirchen J., Fox F., Kündgen A., Nachtkamp K., Strupp C., Haas R., et al. Improved survival in MDS patients receiving iron chelation therapy-a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res 2012, 36:1067-1070.
23. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007, 31(Suppl. 3):S7-S9.
24. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008, 88:24-29.
25. Santini V., Alessandrino P., Angelucci E., Barosi G., Billio A., Di Maio M., et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010, 34:1576-1588.
26. Malcovati L., Hellström-Lindberg E., Bowen D., Adès L., Cermak J., del Cañizo, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013, (prepublished online 26.08.13). 10.1182/blood-2013-03-492884.
27. Delforge M., Selleslag D., Triffet A., Mineur P., Bries G., Graux C., et al. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Ann Hematol 2011, 90:655-666.
28. IBM Corp IBM SPSS Statistics for Mac. 20.0 2011.
29. Lyons R.M., Marek B.J., Paley C., Esposito J., Garbo L., DiBella N., Garcia-Manero G. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res 2014, 38:149-154.
30. Bowen D., Culligan D., Jowitt S., Kelsey S., Mufti G., Oscier D., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187-200.
31. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology - v2.2010. Myelodysplastic syndromes 2010, Available at: https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf [accessed 18.07.13].